论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Fathima M, Saini B, Foster JM, Armour CL
Received 28 June 2017
Accepted for publication 15 August 2017
Published 18 September 2017 Volume 2017:12 Pages 2753—2761
DOI https://doi.org/10.2147/COPD.S145073
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Charles Downs
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Background and objective: Case finding of patients at risk of COPD by community pharmacists
could identify a substantial number of people with undiagnosed COPD, but little
is known about the feasibility and effectiveness of pharmacy-based COPD case
finding using microspirometry. The objective of this study was to assess the
feasibility and effectiveness of COPD case-finding service provided by
community pharmacists, utilizing a combination of risk assessment questionnaire
and microspirometry.
Methods: A 6-month service was conducted in 21 community pharmacies in
Australia. Pharmacists trained in COPD case finding, including lung function
test (LFT), invited their patients aged ≥35 years with a history of
smoking and/or respiratory symptoms to participate. High-risk patients were identified
via a COPD risk assessment questionnaire (Initial Screening Questionnaire
[ISQ]) and underwent LFT. Pharmacists referred patients with a forced
expiratory volume in 1 second (FEV1)/forced
expiratory volume in 6 seconds (FEV6) ratio <0.75
to their general practitioner (GP) for further assessment and diagnosis.
Results: In all, 91 of 167 (54%) patients had an ISQ score >3 indicating
high COPD risk. Of the 157 patients who were able to complete LFT, 61 (39%) had
an FEV1/FEV6 ratio of
<0.75 and were referred to their GP. Patients with high ISQ symptoms scores
(>3) were at a significantly higher risk of an FEV1/FEV6 ratio of
<0.75, compared to patients with fewer COPD symptoms. A total of 15 (10%)
patients were diagnosed with COPD by their GP. Another eight (5%) patients were
diagnosed with other medical conditions and 87% of these were initiated on
treatment. Although only half of all screened patients lived in regional areas,
93% of those diagnosed with COPD were from regional areas.
Conclusion: A brief community pharmacy-based COPD case-finding service
utilizing the ISQ, LFT and GP referral is feasible and may lead to
identification and diagnosis of a substantial number of people with COPD. This
might be an important strategy for reducing the burden of COPD, particularly
for those living in rural locations.
Keywords: COPD, community pharmacy, case finding, case detection, screening